BMO stays on the sidelines as VRX still faces headwinds, but praises key “headway” in growth.
One of Wall Street’s best performing analysts sees strong long-term care growth for ACAD’s Nuplazid.
Oppenheimer remains bearish and full of questions for the HIM team after a rocky 3Q showcase.
Though investor sentiment has turned positive on VRX after 3Q earnings, Wells Fargo makes a bearish case.
MKM notes while fiscal 2019 looks stronger after such a good Q3 from NVIDIA, valuation is not for the bulls.
Susquehanna’s Christopher Rolland boosts price target on NVDA following solid Gaming performance.
Canaccord forecasts DTC marketing could be big for SGYP’s Trulance next year, in footsteps of rival Linzess.
Cantor’s Elemer Piros waits for pass-through reimbursement to be address, before joining the ‘Omeros party’.
H.C.
Ram Selvaraju needs to see more proof of VRX’s pipeline staying power and ability to yield gains.
